Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 4961-4970

  Llano Sotelo, Beatriz ^a,e   Dunkle, Jack ^b   Klepacki, Dorota ^a   Zhang, Wen ^b,f   Fernandes, Prabhavathi ^c   Cate, Jamie H D ^a,b,d   Mankin, Alexander S ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Cempra Pharmaceuticals   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e Nanosphere Inc   (United States)

^f FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BACTERIAL PROTEIN; CEM 101; CEM 103; ERYTHROMYCIN; FLUORINE; LACTONE; MACROLIDE; METHYLTRANSFERASE; PEPTIDYLTRANSFERASE; RNA 23S; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEINOCOCCUS RADIODURANS; DRUG BINDING; DRUG BINDING SITE; DRUG MECHANISM; DRUG STRUCTURE; ESCHERICHIA COLI; HALOARCULA MARISMORTUI; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RIBOSOME; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; WILD TYPE;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, GEL; DEINOCOCCUS; ESCHERICHIA COLI; HALOARCULA MARISMORTUI; MACROLIDES; MOLECULAR STRUCTURE; PROTEIN BIOSYNTHESIS; RIBOSOMES; STAPHYLOCOCCUS AUREUS; TRIAZOLES; X-RAY DIFFRACTION;

EID: 78649681337     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00860-10     Document Type: Article

References (52)

1. Adams, P. D., P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, and P. H. Zwart. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66:213-221.
2. Berisio, R., N. Corti, P. Pfister, A. Yonath, and E. C. Bottger. 2006. 23S rRNA 2058A → G alteration mediates ketolide resistance in combination with deletion in L22. Antimicrob. Agents Chemother. 50:3816-3823.
3. Berisio, R., J. Harms, F. Schluenzen, R. Zarivach, H. A. Hansen, P. Fucini, and A. Yonath. 2003. Structural insight into the antibiotic action of telithromycin against resistant mutants. J. Bacteriol. 185:4276-4279. (Pubitemid 36835269)
4. Böttger, E. C. 2006. The ribosome as a drug target. Trends Biotechnol. 24:145-147.
5. Bryskier, A. 2000. Ketolides - telithromycin, an example of a new class of antibacterial agents. Clin. Microbiol. Infect. 6:661-669.
6. Canu, A., B. Malbruny, M. Coquemont, T. A. Davies, P. C. Appelbaum, and R. Leclercq. 2002. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:125-131.
7. Chittum, H. S., and W. S. Champney. 1994. Ribosomal protein gene sequence changes in erythromycin-resistant mutants of Escherichia coli. J. Bacteriol. 176:6192-6198.
8. Douthwaite, S., and C. Aagaard. 1993. Erythromycin binding is reduced in ribosomes with conformational alterations in the 23S rRNA peptidyl transferase loop. J. Mol. Biol. 232:725-731.
9. Douthwaite, S., L. H. Hansen, and P. Mauvais. 2000. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol. Microbiol. 36:183-193.
10. Douthwaite, S., J. Jalava, and L. Jakobsen. 2005. Ketolide resistance in Streptococcus pyogenes correlates with the degree of rRNA dimethylation by Erm. Mol. Microbiol. 58:613-622.
11. Dunkle, J. A., L. Xiong, A. S. Mankin, and J. H. D. Cate. 27 September 2010. Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action. Proc. Natl. Acad. Sci. U. S. A. [Epub ahead of print.]
12. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
13. Franceschi, F., Z. Kanyo, E. C. Sherer, and J. Sutcliffe. 2004. Macrolide resistance from the ribosome perspective. Curr. Drug Targets Infect. Disord. 4:177-191.
14. Garza-Ramos, G., L. Xiong, P. Zhong, and A. Mankin. 2002. Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J. Bacteriol. 183:6898-6907.
15. Gaynor, M., and A. S. Mankin. 2003. Macrolide antibiotics: binding site, mechanism of action, resistance. Curr. Top. Med. Chem. 3:949-961.
16. Gentry, D. R., and D. J. Holmes. 2008. Selection for high-level telithromycin resistance in Staphylococcus aureus yields mutants resulting from an rplB-to-rplV gene conversion-like event. Antimicrob. Agents Chemother. 52:1156-1158.
17. Hansen, L. H., P. Mauvais, and S. Douthwaite. 1999. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol. Microbiol. 31:623-632.
18. Hisanaga, T., D. J. Hoban, and G. G. Zhanel. 2005. Mechanisms of resistance to telithromycin in Streptococcus pneumoniae. J. Antimicrob. Chemother. 56:447-450.
19. Karahalios, P., D. L. Kalpaxis, H. Fu, L. Katz, D. N. Wilson, and G. P. Dinos. 2006. On the mechanism of action of 9-O-arylalkyloxime derivatives of 6-O-mycaminosyltylonolide, a new class of 16-membered macrolide antibiotics. Mol. Pharmacol. 70:1271-1280.
20. Keyes, R. F., J. J. Carter, E. E. Englund, M. M. Daly, G. G. Stone, A. M. Nilius, and Z. Ma. 2003. Synthesis and antibacterial activity of 6-O-arylbutynyl ketolides with improved activity against some key erythromycin-resistant pathogens. J. Med. Chem. 46:1795-1798.
21. Kouvela, E. C., D. L. Kalpaxis, D. N. Wilson, and G. P. Dinos. 2009. Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity. Antimicrob. Agents Chemother. 53:1411-1419.
22. Kuroda, M., T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya, C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu. 2001. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357:1225-1240.
23. Liu, M., and S. Douthwaite. 2002. Activity of the ketolide telithromycin is refractory to Erm monomethylation of bacterial rRNA. Antimicrob. Agents Chemother. 46:1629-1633.
24. Lovmar, M., K. Nilsson, E. Lukk, V. Vimberg, T. Tenson, and M. Ehrenberg. 2009. Erythromycin resistance by L4/L22 mutations and resistance masking by drug efflux pump deficiency. EMBO J. 28:736-744.
25. Mankin, A. S. 2008. Macrolide myths. Curr. Opin. Microbiol. 11:414-421.
26. McGhee, P., C. Clark, K. M. Kosowska-Shick, K. Nagai, B. Dewasse, L. Beachel, and P. C. Appelbaum. 2010. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob. Agents Chemother. 54:230-238.
27. Merryman, C., and H. F. Noller. 1998. Footprinting and modification-interference analysis of binding sites on RNA, p. 237-253. In C. W. J. Smith (ed.), RNA:protein interactions, a practical approach. Oxford University Press, Oxford, United Kingdom.
28. Moazed, D., and H. F. Noller. 1987. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie 69:879-884.
29. Moore, S. D., and R. T. Sauer. 2008. Revisiting the mechanism of macrolide-antibiotic resistance mediated by ribosomal protein L22. Proc. Natl. Acad. Sci. U. S. A. 105:18261-18266.
30. Novotny, G. W., L. Jakobsen, N. M. Andersen, J. Poehlsgaard, and S. Douthwaite. 2004. Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA. Antimicrob. Agents Chemother. 48:3677-3683.
31. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326. (Pubitemid 27085611)
32. Poehlsgaard, J., and S. Douthwaite. 2003. Macrolide antibiotic interaction and resistance on the bacterial ribosome. Curr. Opin. Invest. Drugs 4:140-148.
33. Poehlsgaard, J., P. Pfister, E. C. Bottger, and S. Douthwaite. 2005. Molecular mechanisms by which rRNA mutations confer resistance to clindamycin. Antimicrob. Agents Chemother. 49:1553-1555.
34. Putnam, S. D., M. Castanheira, G. J. Moet, D. J. Farrell, and R. N. Jones. 2010. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 66:393-401.
35. Rafie, S., C. MacDougall, and C. L. James. 2010. Cethromycin: a promising new ketolide antibiotic for respiratory infections. Pharmacotherapy 30:290-303.
36. Sander, P., L. Belova, Y. G. Kidan, P. Pfister, A. S. Mankin, and E. C. Bottger. 2002. Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations. Mol. Microbiol. 46:1295-1304.
37. Schlunzen, F., J. M. Harms, F. Franceschi, H. A. Hansen, H. Bartels, R. Zarivach, and A. Yonath. 2003. Structural basis for the antibiotic activity of ketolides and azalides. Structure 11:329-338.
38. Schuwirth, B. S., M. A. Borovinskaya, C. W. Hau, W. Zhang, A. Vila-Sanjurjo, J. M. Holton, and J. H. Cate. 2005. Structures of the bacterial ribosome at 3.5 Å resolution. Science 310:827-834.
39. Spedding, G. 1990. Isolation and analysis of ribosomes from prokaryotes, eukaryotes, and organelles, p. 1-29. In G. Spedding (ed.), Ribosomes and protein synthesis, a practical approach. Oxford University Press, Oxford, United Kingdom.
40. Starosta, A. L., V. V. Karpenko, A. V. Shishkina, A. Mikolajka, N. V. Sumbatyan, F. Schluenzen, G. A. Korshunova, A. A. Bogdanov, and D. N. Wilson. 2010. Interplay between the ribosomal tunnel, nascent chain, and macrolides influences drug inhibition. Chem. Biol. 17:504-514.
41. Sutcliffe, J. A. 2005. Improving on nature: antibiotics that target the ribosome. Curr. Opin. Microbiol. 8:534-542.
42. Tenson, T., and A. S. Mankin. 2001. Short peptides conferring resistance to macrolide antibiotics. Peptides 22:1661-1668.
43. Tu, D., G. Blaha, P. B. Moore, and T. A. Steitz. 2005. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 121:257-270.
44. Vazquez, D. 1979. Inhibitors of protein biosynthesis. Springer-Verlag, Berlin, Germany.
45. Vester, B., and S. Douthwaite. 1994. Domain V of 23S rRNA contains all the structural elements necessary for recognition by the ErmE methyltransferase. J. Bacteriol. 176:6999-7004.
46. Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577-585.
47. Wilson, D. N., J. M. Harms, K. H. Nierhaus, F. Schlunzen, and P. Fucini. 2005. Species-specific antibiotic-ribosome interactions: implications for drug development. Biol. Chem. 386:1239-1252.
48. Xiong, L., Y. Korkhin, and A. S. Mankin. 2005. Binding site of the bridged macrolides in the Escherichia coli ribosome. Antimicrob. Agents Chemother. 49:281-288.
49. Xiong, L., S. Shah, P. Mauvais, and A. S. Mankin. 1999. A ketolide resistance mutation in domain II of 23S rRNA reveals proximity of hairpin 35 to the peptidyl transferase centre. Mol. Microbiol. 31:633-639.
50. Zaman, S., M. Fitzpatrick, L. Lindahl, and J. Zengel. 2007. Novel mutations in ribosomal proteins L4 and L22 that confer erythromycin resistance in Escherichia coli. Mol. Microbiol. 66:1039-1050. (Pubitemid 350050427)
51. Zhang, W., J. A. Dunkle, and J. H. Cate. 2009. Structures of the ribosome in intermediate states of ratcheting. Science 325:1014-1017.
52. Zhong, P., Z. Cao, R. Hammond, Y. Chen, J. Beyer, V. D. Shortridge, L. Y. Phan, S. Pratt, J. Capobianco, K. A. Reich, R. K. Flamm, Y. S. Or, and L. Katz. 1999. Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides. Microb. Drug Resist. 5:183-188.